Fonar Corporation (FONR)vsNatera Inc (NTRA)
FONR
Fonar Corporation
$19.09
-0.10%
HEALTHCARE · Cap: $120.20M
NTRA
Natera Inc
$215.31
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 2274% more annual revenue ($2.50B vs $105.34M). FONR leads profitability with a 6.3% profit margin vs -9.1%. FONR earns a higher WallStSmart Score of 38/100 (F).
FONR
Hold38
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.8%
Fair Value
$14.65
Current Price
$19.09
$4.44 premium
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of 5.5% — below average capital efficiency
6.3% margin — thin
Weak financial health signals
Trading at 17.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : FONR
The strongest argument for FONR centers on Price/Book, Altman Z-Score, Debt/Equity.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : FONR
The primary concerns for FONR are Market Cap, Return on Equity, Profit Margin.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
FONR profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.54 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Bottom Line
FONR scores higher overall (38/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fonar Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
FONAR Corporation is engaged in the research, development, production, and marketing of Magnetic Resonance Imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company is headquartered in Melville, New York.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?